Why the study?
Although DOAC therapy causes hemorrhages less frequently than indirect anticoagulants, bleeding still occurs and creates an urgent need for antidotes during spontaneous bleeding, surgery, trauma, or organ failure.
This review outlines the available specific antidotes and non-specific therapies for managing life-threatening bleeding complications in patients treated with direct oral anticoagulants.
Answers are grounded in this paper and cite their sources.
Provides clinicians a synthesis for DOAC bleeding management; leaves open comparative trials of antidotes.
Review presents data on medicines from the new group of cardiovascular drugs, direct oral anticoagulants (DOACs) inhibitors, as antidotes for DOAC when stopping life-threatening bleeding. DOAC therapy is accorded by hemorrhages with lower frequency than therapy by indirect anticoagulants, but really exist. New antidotes for DOACs are idarucizumab, andexanet, ciraparantag. The need in antidotes for DOAC may suddenly appear in spontaneous bleeding, during surgical operation, invasive procedure, due to trauma, in patients with stroke, kidney or liver failure. Data is given on the frequency of the main types of bleeding while taking new oral anticoagulants. Information concerning use of antidotes for DOACs in bleedings as well as use of non-specific therapy are reviewed.
No takes yet. Share an insight, caveat, or question.
Сумароков et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: